RESUMO
Pseudomonas aeruginosa as a common pathogen causing urinary tract infections (UTIs) has been resistant to different antibiotics and developing an effective vaccine can be an alternative strategy. In the present study, the immunogenicity and protection efficacy of formulations composed of a hybrid protein composed of P. aeruginosa V-antigen (PcrV) and exoenzyme S (ExoS) with alum and MPL were evaluated. The hybrid protein could increase the specific systemic and mucosal immune responses, as well as cellular responses as compared with control groups. Combining of alum or MPL adjuvant with the hybrid protein significantly improved the levels of IgG1, serum IgA, mucosal IgG, and IL-17 as compared to the ExoS.PcrV alone. After bladder challenge with a P. aeruginosa strain, the bacterial loads of bladder and kidneys were significantly decreased in mice received ExoS.PcrV admixed with alum and ExoS.PcrV admixed with MPL than controls. The present study indicated that immunization of mice with a hybrid protein composed of ExoS and PcrV could induce multifactorial immune responses and opsonize the bacteria and decrease the viable bacterial cells. Because P. aeruginosa have caused therapeutic challenges worldwide, our study proposed ExoS.PcrV + alum and ExoS.PcrV + MPL as promising candidates for the prevention of infections caused by P. aeruginosa.
Assuntos
ADP Ribose Transferases/imunologia , Adjuvantes Imunológicos/farmacologia , Antígenos de Bactérias/imunologia , Toxinas Bacterianas/imunologia , Proteínas Citotóxicas Formadoras de Poros/imunologia , Infecções por Pseudomonas , Pseudomonas aeruginosa/efeitos dos fármacos , Animais , Camundongos , Camundongos Endogâmicos BALB C , Infecções por Pseudomonas/imunologia , Infecções por Pseudomonas/prevenção & controleRESUMO
On murine T cells, mono-ADP ribosyltransferase ARTC2.2 catalyzes ADP-ribosylation of various surface proteins when nicotinamide adenine dinucleotide (NAD+) is released into the extracellular compartment. Covalent ADP-ribosylation of the P2X7 receptor by ARTC2.2 thereby represents an additional mechanism of activation, complementary to its triggering by extracellular ATP. P2X7 is a multifaceted receptor that may represents a potential target in inflammatory, and neurodegenerative diseases, as well as in cancer. We present herein an experimental approach using intramuscular injection of recombinant AAV vectors (rAAV) encoding nanobody-based biologics targeting ARTC2.2 or P2X7. We demonstrate the ability of these in vivo generated biologics to potently and durably block P2X7 or ARTC2.2 activities in vivo, or in contrast, to potentiate NAD+- or ATP-induced activation of P2X7. We additionally demonstrate the ability of rAAV-encoded functional heavy chain antibodies to elicit long-term depletion of T cells expressing high levels of ARTC2.2 or P2X7. Our approach of using rAAV to generate functional nanobody-based biologics in vivo appears promising to evaluate the role of ARTC2.2 and P2X7 in murine acute as well as chronic disease models.
Assuntos
ADP Ribose Transferases , Produtos Biológicos/imunologia , Dependovirus , Vetores Genéticos , Depleção Linfocítica , Receptores Purinérgicos P2X7/imunologia , Anticorpos de Domínio Único , ADP Ribose Transferases/antagonistas & inibidores , ADP Ribose Transferases/imunologia , Animais , Camundongos , Anticorpos de Domínio Único/genética , Anticorpos de Domínio Único/imunologiaAssuntos
ADP Ribose Transferases/genética , Códon sem Sentido , Proteínas de Membrana/genética , ADP Ribose Transferases/imunologia , Adolescente , Alelos , Tipagem e Reações Cruzadas Sanguíneas , DNA Complementar/genética , Feminino , Mutação da Fase de Leitura , Hemofilia A/complicações , Humanos , Isoanticorpos/sangue , Articulação do Joelho/cirurgia , Masculino , Proteínas de Membrana/imunologia , Pais , Fenótipo , Mutação Puntual , Deleção de Sequência , SíriaRESUMO
Several candidate vaccines against Shigella spp. are in development, but the lack of a clear correlate of protection from challenge with the induction of adequate immune responses among the youngest age groups in the developing world has hampered Shigella vaccine development over the past several decades. Bioconjugation technology, exploited here for an Shigella flexneri 2a candidate vaccine, offers a novel and potentially cost-effective way to develop and produce vaccines against a major pathogen of global health importance. Flexyn2a, a novel S. flexneri 2a bioconjugate vaccine made of the polysaccharide component of the S. flexneri 2a O-antigen, conjugated to the exotoxin protein A of Pseudomonas aeruginosa (EPA), was evaluated for safety and immunogenicity among healthy adults in a single-blind, phase I study with a staggered randomization approach. Thirty subjects (12 receiving 10 µg Flexyn2a, 12 receiving Flexyn2a with aluminum adjuvant, and 6 receiving placebo) were administered two injections 4 weeks apart and were followed for 168 days. Flexyn2a was well-tolerated, independently of the adjuvant and number of injections. The Flexyn2a vaccine elicited statistically significant S. flexneri 2a lipopolysaccharide (LPS)-specific humoral responses at all time points postimmunization in all groups that received the vaccine. Elicited serum antibodies were functional, as evidenced by bactericidal activity against S. flexneri 2a. The bioconjugate candidate vaccine Flexyn2a has a satisfactory safety profile and elicited a robust humoral response to S. flexneri 2a LPS with or without inclusion of an adjuvant. Moreover, the bioconjugate also induced functional antibodies, showing the technology's features in producing a promising candidate vaccine. (This study has been registered at ClinicalTrials.gov under registration no. NCT02388009.).
Assuntos
Anticorpos Antibacterianos/sangue , Disenteria Bacilar/prevenção & controle , Imunogenicidade da Vacina , Vacinas contra Shigella/efeitos adversos , Vacinas contra Shigella/imunologia , Shigella flexneri/imunologia , ADP Ribose Transferases/genética , ADP Ribose Transferases/imunologia , Adolescente , Adulto , Anticorpos Antibacterianos/imunologia , Proteínas de Bactérias/imunologia , Toxinas Bacterianas/genética , Toxinas Bacterianas/imunologia , Disenteria Bacilar/imunologia , Exotoxinas/genética , Exotoxinas/imunologia , Feminino , Voluntários Saudáveis , Humanos , Imunoglobulina A/imunologia , Lipopolissacarídeos/imunologia , Masculino , Pessoa de Meia-Idade , Antígenos O/imunologia , Vacinas contra Shigella/administração & dosagem , Shigella sonnei/imunologia , Método Simples-Cego , Vacinas Conjugadas/administração & dosagem , Vacinas Conjugadas/efeitos adversos , Vacinas Conjugadas/imunologia , Fatores de Virulência/genética , Fatores de Virulência/imunologia , Adulto Jovem , Exotoxina A de Pseudomonas aeruginosaRESUMO
BACKGROUND: Extra-intestinal pathogenic Escherichia coli (ExPEC) are major human pathogens; however, no protective vaccine is currently available. We assessed in animal models the immunogenicity and safety of a 4-valent E. coli conjugate vaccine (ExPEC-4V, serotypes O1, O2, O6 and O25 conjugated to Exotoxin A from Pseudomonas aeruginosa (EPA)) produced using a novel in vivo bioconjugation method. METHODS: Three doses of ExPEC-4V (with or without aluminum hydroxide) were administered to rabbits (2µg or 20µg per O-antigen, subcutaneously), mice (0.2µg or 2µg per O-antigen, subcutaneously) and rats (0.4µg or 4µg per O-antigen, intramuscularly). Antibody persistence and boostability were evaluated in rats using O6-EPA monovalent conjugate (0.4µg O-antigen/dose, intramuscularly). Toxicity was assessed in rats (16µg total polysaccharide, intramuscularly). Serum IgG and IgM antibodies were measured by ELISA. RESULTS: Robust antigen-specific IgG responses were observed in all animal models, with increased responses in rabbits when administered with adjuvant. O antigen-specific antibody responses persisted up to 168days post-priming. Booster immunization induced a rapid recall response. Toxicity of ExPEC-4V when administered to rats was considered to be at the no observed adverse effect level. CONCLUSIONS: ExPEC-4V conjugate vaccine showed good immunogenicity and tolerability in animal models supporting progression to clinical evaluation.
Assuntos
Infecções por Escherichia coli/prevenção & controle , Vacinas contra Escherichia coli/imunologia , Imunogenicidade da Vacina , Antígenos O/imunologia , ADP Ribose Transferases/imunologia , Adjuvantes Imunológicos/administração & dosagem , Animais , Anticorpos Antibacterianos/sangue , Toxinas Bacterianas/imunologia , Escherichia coli , Exotoxinas/imunologia , Feminino , Imunização Secundária , Camundongos , Camundongos Endogâmicos ICR , Nível de Efeito Adverso não Observado , Coelhos , Ratos , Ratos Sprague-Dawley , Testes de Toxicidade , Vacinas Conjugadas/imunologia , Fatores de Virulência/imunologia , Exotoxina A de Pseudomonas aeruginosaRESUMO
The ability to identify immunogenic determinants that activate T-cells is important for the development of new vaccines, allergy therapy and protein therapeutics. In silico MHC-II binding prediction algorithms are often used for T-cell epitope identification. To understand how well those programs predict immunogenicity, we computed HLA binding to peptides spanning the sequence of PE38, a fragment of an anti-cancer immunotoxin, and compared the predicted and experimentally identified T-cell epitopes. We found that the prediction for individual donors did not correlate well with the experimental data. Furthermore, prediction of T-cell epitopes in an HLA heterogenic population revealed that the two strongest epitopes were predicted at multiple cutoffs but the third epitope was predicted negative at all cutoffs and overall 4/9 epitopes were missed at several cutoffs. We conclude that MHC class-II binding predictions are not sufficient to predict the T-cell epitopes in PE38 and should be supplemented by experimental work.
Assuntos
ADP Ribose Transferases/imunologia , Toxinas Bacterianas/imunologia , Epitopos de Linfócito T/imunologia , Exotoxinas/imunologia , Antígenos HLA-DR/imunologia , Ativação Linfocitária/imunologia , Ligação Proteica/imunologia , Pseudomonas/imunologia , Linfócitos T/imunologia , Fatores de Virulência/imunologia , Algoritmos , Sequência de Aminoácidos , Formação de Anticorpos/imunologia , Sítios de Ligação/imunologia , Humanos , Dados de Sequência Molecular , Peptídeos/imunologia , Exotoxina A de Pseudomonas aeruginosaRESUMO
Amongst the pathologies associated with infection by Kaposi's sarcoma-associated herpesvirus (KSHV), multicentric Castleman's disease is distinctive for involvement of the lytic phase of the virus replication cycle. This B cell lymphoproliferative disorder has shown clinical responsiveness not only to generalized immunotherapy and cytotoxic chemotherapy, but also to inhibitors of herpesvirus DNA replication, consistent with the involvement of lytic phase of replication. These findings suggest that selective killing of virus-producing cells might represent a novel therapeutic strategy. We designed an immunotoxin, YC15-PE38, containing a single chain variable region fragment of a monoclonal antibody against KSHV glycoprotein H (gH) linked to the effector domains of Pseudomonas aeruginosa exotoxin A. Purified YC15-PE38 displayed highly selective and potent killing of a gH-expressing transfectant cell line (subnanomolar IC(50)). The immunotoxin also strongly inhibited production of infectious KSHV virions from an induced chronically infected cell line, by virtue of selective killing of the virus-producing cells. Combination treatment studies indicated complementary activities between YC15-PE38 and the herpesviral DNA replication inhibitor ganciclovir. These results provide support for the development of anti-KSHV strategies based on targeted killing of infected cells expressing lytic phase genes.
Assuntos
ADP Ribose Transferases/uso terapêutico , Toxinas Bacterianas/uso terapêutico , Citotoxicidade Imunológica , Exotoxinas/uso terapêutico , Infecções por Herpesviridae/tratamento farmacológico , Infecções por Herpesviridae/imunologia , Herpesvirus Humano 8/fisiologia , Imunotoxinas/uso terapêutico , Proteínas do Envelope Viral/imunologia , Fatores de Virulência/uso terapêutico , ADP Ribose Transferases/genética , ADP Ribose Transferases/imunologia , Toxinas Bacterianas/genética , Toxinas Bacterianas/imunologia , Linhagem Celular , Exotoxinas/genética , Exotoxinas/imunologia , Infecções por Herpesviridae/virologia , Herpesvirus Humano 8/efeitos dos fármacos , Herpesvirus Humano 8/genética , Humanos , Imunotoxinas/genética , Imunotoxinas/imunologia , Proteínas do Envelope Viral/genética , Fatores de Virulência/genética , Fatores de Virulência/imunologia , Replicação Viral , Exotoxina A de Pseudomonas aeruginosaRESUMO
Rheumatoid arthritis is a proinflammatory autoimmune disease attributed to failure of both CD4(+)CD25(+) regulatory T (Tr) and CD8(+)CD28(-) suppressor T (Ts) cells to control autoreactive CD4(+)CD28(+) Th1 (Th1) and autoantibody-producing B cells. Here we show a single intramuscular injection of our novel targeted DNA vaccine encoding Pseudomonas exotoxin A and costimulatory molecule B7-2 without autoantigens in a collagen-induced arthritis model simultaneously increased Tr and Ts cells and selectively decreased autoreactive Th1 cells. The vaccine induced a shift from Th1 to Th2 and Th3 cellular and cytokine profiles and a decrease in CD4(+)/CD8(+) cell ratios. Importantly, the vaccine showed potent antirheumatic activity by clinical and other examinations such as X-ray, histopathology, and anti-type II collagen IgG levels and was comparable to methotrexate, the current "gold standard" treatment. As an effective stimulator of both Tr and Ts cells and a specific suppressor of autoreactive Th1 cells, this vaccine is a promising therapeutic approach for rheumatoid arthritis.
Assuntos
ADP Ribose Transferases/administração & dosagem , Antirreumáticos/imunologia , Artrite Reumatoide/prevenção & controle , Antígeno B7-2/administração & dosagem , Toxinas Bacterianas/administração & dosagem , Antígenos CD28/imunologia , Exotoxinas/administração & dosagem , Vacinas de DNA/imunologia , Fatores de Virulência/administração & dosagem , ADP Ribose Transferases/imunologia , Animais , Antirreumáticos/metabolismo , Artrite Experimental/imunologia , Artrite Reumatoide/imunologia , Antígeno B7-2/imunologia , Toxinas Bacterianas/imunologia , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Citocinas/imunologia , Exotoxinas/imunologia , Feminino , Ratos , Ratos Wistar , Transdução de Sinais , Linfócitos T Reguladores/imunologia , Células Th1/imunologia , Células Th2/imunologia , Vacinas de DNA/metabolismo , Fatores de Virulência/imunologia , Exotoxina A de Pseudomonas aeruginosaRESUMO
Synthetic peptides derived from the G-H loop of the foot and mouth disease virus (FMDV) capsid protein VP1 are relatively poor at recapitulating the native conformation present in the virus, and thus are often poor immunogens. We hypothesized that a candidate mucosal vaccine against FMDV could be developed using the non-toxic Pseudomonas aeruginosa exotoxin A (ntPE) to deliver the G-H loop in its native conformation. An added benefit of this approach is the potential for ntPE to serve as an effective carrier/adjuvant molecule for delivery of the fusion protein across the epithelial barrier by virtue of its capacity to bind to CD91. A chimeric protein (ntPE-GH) was generated by inserting the coding sequence of the G-H loop into an expression plasmid encoding ntPE, in place of the native Ib loop. Recombinant ntPE-GH and wild-type ntPE were each expressed in Escherichia coli, purified over a nickel resin, then administered intranasally to the pigs, with or without the mucosal adjuvant cholera toxin (CT). Both the ntPE and ntPE-GH induced mucosal and systemic immune responses against ntPE; moreover, ntPE-GH administered without CT induced anti-GH loop serum IgG antibodies. In conclusion, these data demonstrate that ntPE can be used as a mucosal carrier/adjuvant to induce an immune response against the VP1 G-H loop of FMDV.
Assuntos
ADP Ribose Transferases/imunologia , Toxinas Bacterianas/imunologia , Proteínas do Capsídeo/imunologia , Exotoxinas/imunologia , Vírus da Febre Aftosa/imunologia , Proteínas Recombinantes de Fusão/imunologia , Vacinas Sintéticas/imunologia , Vacinas Virais/imunologia , Fatores de Virulência/imunologia , ADP Ribose Transferases/genética , Administração Intranasal , Animais , Anticorpos Antivirais/sangue , Toxinas Bacterianas/genética , Proteínas do Capsídeo/química , Proteínas do Capsídeo/genética , Exotoxinas/genética , Feminino , Masculino , Suínos , Vacinação , Fatores de Virulência/genética , Exotoxina A de Pseudomonas aeruginosaRESUMO
LHRH-PE40, a recombinant DNA-derived protein composed of LHRH and Pseudomonas aeruginosa exotoxin A, is being developed for the treatment of malignant tumours. This experiment was designed to assess its preclinical safety. Reproductive toxicity studies, pharmacokinetic studies, single- and repeat-dose intraperitoneal or intravenous toxicity studies in mice, rats and monkeys were conducted to assess the toxicity of LHRH-PE40. In intravenous single-dose studies in mice, the LD50 was 731.26 microg/kg and 676.03 microg/kg in male and female mice respectively. In single-dose studies and repeat-dose range-finding studies in rats, dose-limited severe vascular leakage syndromes occurred. In repeat-dose long-term studies, except drug-related vascular leakage syndromes, other drug-related changes included decreased testis weight and testis atrophy. In single-dose and repeat-dose studies in monkeys, dose-limited acute tubular necrosis of the kidneys was the chief finding. In reproductive studies, drug-related changes were decreased food intakes, decreased testis weight and uterus weight, decreased foetus weight and increased foetus mortality, increased maternal and F1 offspring mortality and decreased maternal and F1 offspring body weight. Pharmacokinetic studies showed a similar half-time of distribution and clearance in mice and monkeys. Tissue distribution showed a high concentration in the kidneys and a low concentration in the brain. LHRH-PE40 induced vascular leak syndromes in rats and acute tubular necrosis in monkeys. It also led to testicle atrophy in rats and overt productive toxicity to parents and F1 generations in mice. Because of these findings, it should be monitored carefully in human clinical trials for things such as respiratory, urinary and reproductive toxicities.
Assuntos
ADP Ribose Transferases/toxicidade , Antineoplásicos/toxicidade , Toxinas Bacterianas/toxicidade , Exotoxinas/toxicidade , Hormônio Liberador de Gonadotropina/toxicidade , Proteínas Recombinantes de Fusão/toxicidade , Fatores de Virulência/toxicidade , ADP Ribose Transferases/imunologia , ADP Ribose Transferases/farmacocinética , Animais , Anticorpos/sangue , Antineoplásicos/imunologia , Antineoplásicos/farmacocinética , Toxinas Bacterianas/imunologia , Toxinas Bacterianas/farmacocinética , Avaliação Pré-Clínica de Medicamentos , Exotoxinas/imunologia , Exotoxinas/farmacocinética , Feminino , Hormônio Liberador de Gonadotropina/imunologia , Hormônio Liberador de Gonadotropina/farmacocinética , Rim/efeitos dos fármacos , Rim/patologia , Pulmão/efeitos dos fármacos , Pulmão/patologia , Macaca fascicularis , Masculino , Camundongos , Camundongos Endogâmicos , Camundongos Nus , Neoplasias/tratamento farmacológico , Tamanho do Órgão/efeitos dos fármacos , Gravidez , Ratos , Ratos Wistar , Proteínas Recombinantes de Fusão/imunologia , Proteínas Recombinantes de Fusão/farmacocinética , Reprodução/efeitos dos fármacos , Testículo/efeitos dos fármacos , Testículo/crescimento & desenvolvimento , Testículo/patologia , Útero/efeitos dos fármacos , Útero/crescimento & desenvolvimento , Fatores de Virulência/imunologia , Fatores de Virulência/farmacocinética , Exotoxina A de Pseudomonas aeruginosaRESUMO
ADP-ribosyltransferases (ARTs) transfer ADP-ribose from NAD to arginine, asparagine, or cysteine residues in target proteins. This post-translational protein modification is the mechanism by which cholera-toxin and other bacterial toxins cause pathology in human host cells. Molecular cloning has identified five toxin-related GPI-anchored cell surface ARTs in the mouse (ART1, ART2.1, ART2.2, ART3, and ART4) and three in the human (ART1, ART3, and ART4). ART2-which has sparked interest because of its ability to activate the cytolytic P2X7 purinergic receptor by ADP-ribosylation-is encoded by two functional gene copies in the mouse genome while the human genome carries two inactivated ART2 pseudogenes. We generated stable transfectants for FLAG-tagged versions of each of the functional human and mouse ARTs. Using genetic immunization we raised monoclonal antibodies that recognize the native human ARTs on the surface of living cells. Some of these mAbs recognize an epitope shared with the mouse ART orthologue but not with more distant ART paralogues. Screening of primary cells and established cell lines by FACS revealed expression of ART1 by monocytes, neutrophils and myeloid leukemia cell lines but not by cell lines derived from solid tumors. ART1 and ART4 have been assigned the designations: CD296, and CD297, respectively.
Assuntos
ADP Ribose Transferases/imunologia , ADP Ribose Transferases/genética , ADP Ribose Transferases/metabolismo , Animais , Anticorpos Monoclonais/biossíntese , Anticorpos Monoclonais/imunologia , Especificidade de Anticorpos , Linhagem Celular , DNA Complementar/imunologia , Glicosilfosfatidilinositóis/metabolismo , Humanos , Imunização/métodos , Leucemia Mieloide/metabolismo , Proteínas de Membrana/imunologia , Proteínas de Membrana/metabolismo , Camundongos , Monócitos/metabolismo , Neutrófilos/metabolismo , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/metabolismo , TransfecçãoRESUMO
The in vivo mechanisms of action of most vaccine adjuvants are poorly understood. In this study, we present data in mice that reveal a series of critical interactions between the cholera toxin (CT) adjuvant and the dendritic cells (DC) of the splenic marginal zone (MZ) that lead to effective priming of an immune response. For the first time, we have followed adjuvant targeting of MZ DC in vivo. We used CT-conjugated OVA and found that the Ag selectively accumulated in MZ DC following i.v. injections. The uptake of Ag into DC was GM1 ganglioside receptor dependent and mediated by the B subunit of CT (CTB). The targeted MZ DC were quite unique in their phenotype: CD11c(+), CD8alpha(-), CD11b(-), B220(-), and expressing intermediate or low levels of MHC class II and DEC205. Whereas CTB only delivered the Ag to MZ DC, the ADP-ribosyltransferase activity of CT was required for the maturation and migration of DC to the T cell zone, where these cells distinctly up-regulated CD86, but not CD80. This interaction appeared to instruct Ag-specific CD4(+) T cells to move into the B cell follicle and strongly support germinal center formations. These events may explain why CT-conjugated Ag is substantially more immunogenic than Ag admixed with soluble CT and why CTB-conjugated Ag can tolerize immune responses when given orally or at other mucosal sites.
Assuntos
ADP Ribose Transferases/fisiologia , Adjuvantes Imunológicos/fisiologia , Toxina da Cólera/fisiologia , Células Dendríticas/imunologia , ADP Ribose Transferases/imunologia , Animais , Linfócitos B/imunologia , Diferenciação Celular/imunologia , Movimento Celular/imunologia , Células Cultivadas , Toxina da Cólera/imunologia , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Camundongos Transgênicos , Ovalbumina/imunologia , Receptores de Superfície Celular/imunologia , Baço/citologia , Baço/imunologia , Baço/fisiologia , Linfócitos T/imunologiaRESUMO
Escherichia coli heat-labile enterotoxin (LT), which causes a characteristic diarrhea in humans and animals, is a strong mucosal immunogen and has powerful mucosal adjuvant activity towards coadministered unrelated antigens. Here we report the different mucosal adjuvanticity of nontoxic LT derivatives, LTS63Y and LTdelta110/112, generated by immunizing through two different mucosal routes. Intragastric (IG) immunization with Helicobacter pylori urease alone resulted in poor systemic IgG and IgA responses and no detectable local secretory IgA, but IG co-immunization with urease and LTdelta110/112 induced high titers of urease-specific local secretory IgA and systemic IgG and IgA, comparable to those induced by wild-type LT. LTS63Y showed far lower adjuvant activity towards urease than LTdelta110/112 in IG immunization, but was more active than LTdelta110/112 in inducing immune responses to urease by intranasal (IN) immunization. LTdelta110/112 predominantly enhanced the induction of urease-specific IgG1 levels following IG immunization, whereas LTS63Y induced high levels of IgG1, IgG2a and IgG2b following IN immunization. In addition, quantitative H. pylori culture of stomach tissue following challenge with H. pylori demonstrated a 90-95% reduction (p < 0.0002) in bacterial burden in mice immunized intranasally with urease using either mutant LT as an adjuvant. These results indicate that the mechanism(s) underlying the adjuvant activities of mutant LTs towards coadmnistered H. pylori urease may differ between the IN and IG mucosal immunization routes.
Assuntos
Feminino , Humanos , Camundongos , Adjuvantes Imunológicos/administração & dosagem , Administração Intranasal , Animais , Toxinas Bacterianas/imunologia , Toxinas Bacterianas/genética , Toxinas Bacterianas/administração & dosagem , Enterotoxinas/imunologia , Enterotoxinas/genética , Enterotoxinas/administração & dosagem , Ensaio de Imunoadsorção Enzimática , Escherichia coli , Fezes , Mucosa Gástrica/microbiologia , Mucosa Gástrica/imunologia , Helicobacter pylori , Imunoglobulina A Secretora/imunologia , Imunoglobulina G/imunologia , Camundongos Endogâmicos BALB C , Mutagênese Sítio-Dirigida , ADP Ribose Transferases/imunologia , ADP Ribose Transferases/genética , Mucosa Nasal/imunologia , Mutação Puntual , Urease/imunologia , Urease/administração & dosagem , VacinaçãoRESUMO
mRNA from human polymorphonuclear neutrophil leucocytes (PMNs) was probed with cDNA encoding human skeletal muscle arginine-specific ADP-ribosyltransferase (ART1). A single 2.6-kb transcript was identified, which was similar in size to that observed in human skeletal muscle RNA. An 872-bp cDNA fragment, corresponding to the amino acid sequence of the processed human skeletal muscle enzyme, was generated by reverse transcription-PCR amplification of RNA from human PMNs, and was found to be identical to the ART1 cDNA derived from human skeletal muscle. ART1 was expressed as a fusion protein with glutathione S-transferase (GST) in insect cells, and antibodies were raised against the fusion protein in a rabbit. Following removal of GST immunoreactivity by immunoprecipitation, these antibodies were used to measure the abundance of immunoreactive ART1 on the surface of PMNs. Exposure of PMNs to formyl-Met-Leu-Phe (FMLP) was followed by a rapid increase in the abundance of cell surface ART1 (T1/2 = 1.9 min), and the concentration of FMLP for half-maximum response was 28.6 nM. Similar responses were observed after exposure of the cells to platelet-activating factor or interleukin-8, and we conclude that some of the effects of these chemotaxins are mediated by translocation of an intracellular pool of ART1 to its site of catalytic activity on the outer aspect of the plasma membrane.
Assuntos
ADP Ribose Transferases/metabolismo , Fatores Quimiotáticos/farmacologia , Neutrófilos/enzimologia , ADP Ribose Transferases/imunologia , Animais , Membrana Celular/enzimologia , DNA Complementar/genética , Fluorescência , Humanos , Músculo Esquelético/enzimologia , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Fosfatidilinositol Diacilglicerol-Liase , RNA Mensageiro/metabolismo , Proteínas Recombinantes de Fusão/genética , Spodoptera/genética , Fosfolipases Tipo C/metabolismoRESUMO
Transcutaneous immunization (TCI) is a new technique that uses the application of vaccine antigens in a solution on the skin to induce potent antibody responses without systemic or local toxicity. We have previously shown that cholera toxin (CT), a potent adjuvant for oral and nasal immunization, can induce both serum and mucosal immunoglobulin G (IgG) and IgA and protect against toxin-mediated mucosal disease when administered by the transcutaneous route. Additionally, CT acts as an adjuvant for coadministered antigens such as tetanus and diphtheria toxoids when applied to the skin. CT, a member of the bacterial ADP-ribosylating exotoxin (bARE) family, is most potent as an adjuvant when the A-B subunits are present and functional. We now show that TCI induces secondary antibody responses to coadministered antigens as well as to CT in response to boosting immunizations. IgG antibodies to coadministered antigens were also found in the stools and lung washes of immunized mice, suggesting that TCI may target mucosal pathogens. Mice immunized by the transcutaneous route with tetanus fragment C and CT developed anti-tetanus toxoid antibodies and were protected against systemic tetanus toxin challenge. We also show that bAREs, similarly organized as A-B subunits, as well as the B subunit of CT alone, induced antibody responses to themselves when given via TCI. Thus, TCI appears to induce potent, protective immune responses to both systemic and mucosal challenge and offers significant potential practical advantages for vaccine delivery.